Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation

Oncogene

Volumn 29, Issue 48, 2010, Pages 6378-6389

  Zheng, J ^a   MacHida, K ^a   Antoku, S ^a   Ng, K Y ^a   Claffey, K P ^a   Mayer, B J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Abl family kinase; C3G; SH2 SH3 adaptor; SH3 domain; SOS1

Indexed keywords

ABELSON KINASE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR C3G; GUANINE NUCLEOTIDE EXCHANGE FACTOR DOCK180; IMATINIB; ONCOPROTEIN; PROTEIN CRKI; SHORT HAIRPIN RNA; SOS PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL STRAIN 3T3; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; GUANINE NUCLEOTIDE-RELEASING FACTOR 2; HEK293 CELLS; HUMANS; MALE; MICE; MICE, NUDE; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-CRK; SIGNAL TRANSDUCTION; SOS1 PROTEIN; SRC HOMOLOGY DOMAINS;

MUS MUSCULUS;

EID: 78649834065     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.369     Document Type: Article

References (55)

1. Akagi T, Murata K, Shishido T, Hanafusa H. (2002). v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras. Mol Cell Biol 22: 7015-7023.
2. Akagi T, Shishido T, Murata K, Hanafusa H. (2000). v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proc Natl Acad Sci USA 97: 7290-7295.
3. Antoku S, Mayer BJ. (2009). Distinct roles for Crk adaptor isoforms in actin reorganization induced by extracellular signals. J Cell Sci 122: 4228-4238.
4. Birge RB, Fajardo JE, Reichman C, Shoelson SE, Songyang Z, Cantley LC et al. (1993). Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts. Mol Cell Biol 13: 4648-4656.
5. Cipres A, Abassi YA, Vuori K. (2007). Abl functions as a negative regulator of Met-induced cell motility via phosphorylation of the adapter protein CrkII. Cell Signal 19: 1662-1670.
6. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA et al. (2008). MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373: 607-612.
7. Deakin NO, Turner CE. (2008). Paxillin comes of age. J Cell Sci 121: 2435-2344.
8. Defilippi P, Di Stefano P, Cabodi S. (2006). p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 16: 257-263.
9. Deininger MW, Goldman JM, Lydon N, Melo JV. (1997). The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698.
10. Druker BJ. (2009). Perspectives on the development of imatinib and the future of cancer research. Nat Med 15: 1149-1152.
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
12. Feller SM. (2001). Crk family adaptors-signalling complex formation and biological roles. Oncogene 20: 6348-6371.
13. Feller SM, Knudsen B, Hanafusa H. (1994). c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J 13: 2341-2351.
14. Gotoh T, Hattori S, Nakamura S, Kitayama H, Noda M, Takai Y et al. (1995). Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol 15: 6746-6753.
15. Gotoh T, Niino Y, Tokuda M, Hatase O, Nakamura S, Matsuda M et al. (1997). Activation of R-Ras by Ras-guanine nucleotide-releasing factor. J Biol Chem 272: 18602-18607.
16. Greulich H, Hanafusa H. (1996). A role for Ras in v-Crk transformation. Cell Growth Differ 7: 1443-14451.
17. Hasegawa H, Kiyokawa E, Tanaka S, Nagashima K, Gotoh N, Shibuya M et al. (1996). DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol Cell Biol 16: 1770-1776.
18. Hemmeryckx B, Van Wijk A, Reichert A, Kaartinen V, de Jong R, Pattengale PK et al. (2001). Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res 61: 1398-1405.
19. Innocenti M, Tenca P, Frittoli E, Faretta M, Tocchetti A, Di Fiore PP et al. (2002). Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol 56: 125-136.
20. Iwahara T, Akagi T, Fujitsuka Y, Hanafusa H. (2004). CrkII regulates focal adhesion kinase activation by making a complex with Crk-associated substrate, p130Cas. Proc Natl Acad Sci USA 101: 17693-17698.
21. Iwahara T, Akagi T, Shishido T, Hanafusa H. (2003). CrkII induces serum response factor activation and cellular transformation through its function in Rho activation. Oncogene 22: 5946-5957.
22. Kain K, Klemke R. (2001). Inihibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. J Biol Chem 276: 16185-16192.
23. 0 controlling carcinoma cell survival and invasion. Oncogene 22: 6071-6080.
24. Kobashigawa Y, Sakai M, Naito M, Yokochi M, Kumeta H, Makino Y et al. (2007). Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK. Nat Struct Mol Biol 14: 503-510.
25. Linghu H, Tsuda M, Makino Y, Sakai M, Watanabe T, Ichihara S et al. (2006). Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS. Oncogene 25: 3547-3556.
26. Matsuda M, Hashimoto Y, Muroya K, Hasegawa H, Kurata T, Tanaka S et al. (1994). CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells. Mol Cell Biol 14: 5495-5500.
27. Matsuda M, Ota S, Tanimura R, Nakamura H, Matuoka K, Takenawa T et al. (1996). Interaction between the amino-terminal SH3 domain of CRK and its natural target proteins. J Biol Chem 271: 14468-14472.
28. Matsuda M, Tanaka S, Nagata S, Kojima A, Kurata T, Shibuya M. (1992). Two species of human CRK cDNA encode proteins with distinct biological activities. Mol Cell Biol 12: 3482-3489.
29. Mayer BJ, Hamaguchi M, Hanafusa H. (1988). A novel viral oncogene with structural similarity to phospholipase C. Nature 332: 272-275.
30. Mayer BJ, Hanafusa H. (1990). Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation. J Virol 64: 3581-3589.
31. Miller CT, Chen G, Gharib TG, Wang H, Thomas DG, Misek DE et al. (2003). Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22: 7950-7957.
32. Mochizuki N, Ohba Y, Kobayashi S, Otsuka N, Graybiel AM, Tanaka S et al. (2000). Crk activation of JNK via C3G and R-Ras. J Biol Chem 275: 12667-12671.
33. Nievers MG, Birge RB, Greulich H, Verkleij AJ, Hanafusa H, Van Bergen en Henegouwen PM. (1997). v-Crk-induced cell transformation: changes in focal adhesion composition and signaling. J Cell Sci 110: 389-399.
34. Noren NK, Foos G, Hauser CA, Pasquale EB. (2006). The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8: 815-825.
35. Pendergast AM. (2002). The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85: 51-100.
36. Qian X, Esteban L, Vass WC, Upadhyaya C, Papageorge AG, Yienger K et al. (2000). The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties. EMBO J 19: 642-654.
37. Reichman CT, Mayer BJ, Keshav S, Hanafusa H. (1992). The product of the cellular crk gene consists primarily of SH2 and SH3 regions. Cell Growth Diff 3: 451-460.
38. Ren R, Ye Z-S, Baltimore D. (1994). Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev 8: 783-795.
39. 0-kinase in v-crk-transformed cells. Mol Cancer Res 1: 428-437.
40. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H et al. (1994a). A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 13: 3748-3756.
41. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Nishida J et al. (1994b). Characterization, partial purification, and peptide sequencing of p130,the main phosphoprotein associated with v-Crk oncoprotein. J Biol Chem 269: 32740-32746.
42. Senechal K, Heaney C, Druker B, Sawyers CL. (1998). Structural requirement for function of the Crkl adapter protein in firbroblasts and hematopoietic cells. Mol Cell Biol 18: 5082-5090.
43. Sharma A, Antoku S, Mayer BJ. (2004). The functional interaction trap: a novel strategy to study specific protein-protein interactions. In: Kamp RM, Calvete J and Choli-Papadopoulou T (eds). Methods in Proteome and Protein Analysis (MPSA 2002). Springer-Verlag: Berlin, pp 165-181.
44. Shishido T, Akagi T, Chalmers A, Maeda M, Terada T, Georgescu MM et al. (2001). Crk family adaptor proteins trans-activate c-Abl kinase. Genes Cells 6: 431-440.
45. Stam JC, Geerts WJ, Versteeg HH, Verkleij AJ, Van Bergen en Henegouwen PM. (2001). The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt. J Biol Chem 276: 25176-25183.
46. Takino T, Nakada M, Miyamori H, Yamashita J, Yamada KM, Sato H. (2003). CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res 63: 2335-2337. (Pubitemid 36538646)
47. Tanaka M, Gupta R, Mayer BJ. (1995). Differential inhibition of signaling pathways by dominant-negative SH2/SH3 adapter proteins. Mol Cell Biol 15: 6829-6837.
48. Tanaka S, Morishita T, Hashimoto Y, Hattori S, Nakamura S, Shibuya M et al. (1994). C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc Nat Acad Sci USA 91: 3443-3447.
49. Tanaka S, Ouchi T, Hanafusa H. (1997). Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G. Proc Natl Acad Sci USA 94: 2356-2361.
50. Ten Hoeve J, Morris C, Heisterkamp N, Groffen J. (1993). Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 8: 2469-2474.
51. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A et al. (2004). Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 32: 936-948.
52. Wang B, Mysliwiec T, Feller SM, Knudsen B, Hanafusa H, Kruh GD. (1996). Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk. Oncogene 13: 1379-1385.
53. Wang JY. (2000). Regulation of cell death by the Abl tyrosine kinase. Oncogene 19: 5643-5650.
54. Wang L, Tabu K, Kimura T, Tsuda M, Linghu H, Tanino M et al. (2007). Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. Biochem Biophys Res Commun 362: 976-981.
55. Wang Z, Dillon TJ, Pokala V, Mishra S, Labudda K, Hunter B et al. (2006). Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. Mol Cell Biol 26: 2130-2145.